MA40894A - Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production - Google Patents

Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production

Info

Publication number
MA40894A
MA40894A MA040894A MA40894A MA40894A MA 40894 A MA40894 A MA 40894A MA 040894 A MA040894 A MA 040894A MA 40894 A MA40894 A MA 40894A MA 40894 A MA40894 A MA 40894A
Authority
MA
Morocco
Prior art keywords
lymphocytes
target
production processes
heterodimeric immunoglobulins
heterodimeric
Prior art date
Application number
MA040894A
Other languages
English (en)
French (fr)
Inventor
Jonathan Back
Samuel Hou
Rami Lissilaa
Romain Ollier
Darko Skegro
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/073738 external-priority patent/WO2015063339A1/en
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of MA40894A publication Critical patent/MA40894A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA040894A 2014-11-04 2015-11-02 Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production MA40894A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2014/073738 WO2015063339A1 (en) 2013-11-04 2014-11-04 Production of t cell retargeting hetero-dimeric immunoglobulins
EP15167034 2015-05-08

Publications (1)

Publication Number Publication Date
MA40894A true MA40894A (fr) 2017-09-12

Family

ID=53059011

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040894A MA40894A (fr) 2014-11-04 2015-11-02 Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production

Country Status (20)

Country Link
EP (1) EP3215541A1 (zh)
JP (3) JP2018501297A (zh)
KR (1) KR20170078831A (zh)
CN (1) CN107207596A (zh)
AU (1) AU2015341884B2 (zh)
BR (1) BR112017009263A2 (zh)
CA (1) CA2965745C (zh)
CL (1) CL2017001090A1 (zh)
CO (1) CO2017005240A2 (zh)
EA (1) EA039658B1 (zh)
HK (1) HK1244014A1 (zh)
IL (1) IL251848A0 (zh)
MA (1) MA40894A (zh)
MX (1) MX2017005814A (zh)
MY (1) MY186929A (zh)
NZ (1) NZ732019A (zh)
PE (1) PE20171041A1 (zh)
PH (1) PH12017500819A1 (zh)
SG (1) SG11201703313SA (zh)
WO (1) WO2016071355A1 (zh)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
AU2014205086B2 (en) 2013-01-14 2019-04-18 Xencor, Inc. Novel heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP4067383A1 (en) 2013-07-25 2022-10-05 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
BR112016009919A2 (pt) 2013-11-04 2017-12-05 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma
AP2016009475A0 (en) 2014-03-28 2016-09-30 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
CN107108738A (zh) * 2014-07-25 2017-08-29 西托姆克斯治疗公司 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
MX2017006918A (es) 2014-11-26 2018-01-25 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cd38.
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EP3387013B1 (en) 2015-12-07 2022-06-08 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
RU2767357C2 (ru) 2016-06-14 2022-03-17 Ксенкор, Инк. Биспецифические антитела-ингибиторы контрольных точек
US20230159661A1 (en) * 2017-04-24 2023-05-25 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
CA3064163A1 (en) 2017-06-05 2018-12-13 Numab Therapeutics AG Novel anti-cd3 antibodies
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
WO2018224682A1 (en) 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody
EP3635003A1 (en) * 2017-06-08 2020-04-15 Black Belt Therapeutics Limited Cd38 modulating antibody
CN117820498A (zh) * 2017-08-10 2024-04-05 盖立复诊断解决方案公司 包含重组人类cd38细胞外结构域的组合物、方法和/或试剂盒
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
SG11202000484TA (en) 2017-08-16 2020-02-27 Black Belt Therapeutics Ltd Cd38 antibody
KR20200064096A (ko) 2017-10-14 2020-06-05 싸이톰스 테라퓨틱스, 인크. 항체, 활성화 가능한 항체, 이중특이적 항체 및 이중특이적 활성화 가능한 항체 및 이들의 사용 방법
KR20210075101A (ko) * 2018-09-25 2021-06-22 아이크노스 사이언스 에스. 아. 생물학적 샘플에서의 항체 정량법
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
WO2020152290A1 (en) * 2019-01-23 2020-07-30 Encefa Cd31 competitors and uses thereof
US20220177582A1 (en) * 2019-03-13 2022-06-09 Ichnos Sciences SA Non-consensus glycosylation of bispecific antibodies
US20220227866A1 (en) * 2019-05-23 2022-07-21 VelosBio Inc. Anti-ror1 / anti-cd3 bispecific binding molecules
WO2020250940A1 (ja) * 2019-06-11 2020-12-17 小野薬品工業株式会社 免疫抑制剤
CN110551222B (zh) * 2019-08-27 2023-06-06 重庆市畜牧科学院 一种新型双功能抗体及其用途
KR20220071263A (ko) * 2019-09-30 2022-05-31 하버 바이오메드 (쑤저우) 컴퍼니 리미티드 Cd3을 표적으로 하는 항체, 이중 특이성 항체 및 이의 용도
CN113493519B (zh) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
JP2023523584A (ja) * 2020-04-24 2023-06-06 メモリアル スローン ケタリング キャンサー センター 抗ｃｄ３抗体及びその使用
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CA3180690A1 (en) * 2020-06-17 2021-12-23 Ahmed Mahiuddin Cd38 antibodies for treatment of human diseases
WO2022040482A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54056B1 (en) * 2004-02-06 2015-10-30 Morphosys Ag ANTI-CD38 HUMAN ANTIBODIES AND THEIR USES
SI2567976T1 (sl) * 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
EP3284756B1 (en) * 2005-10-12 2021-05-05 MorphoSys AG Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN103833855A (zh) * 2009-06-26 2014-06-04 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
CA2785414C (en) * 2009-12-25 2019-01-22 Tomoyuki Igawa Polypeptide modification method for purifying polypeptide multimers
JP6093696B2 (ja) * 2010-06-09 2017-03-08 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CA2812739A1 (en) * 2011-03-25 2012-10-04 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
IN2015MN00139A (zh) * 2012-09-25 2015-10-16 Glenmark Pharmaceuticals Sa
WO2014068114A1 (en) * 2012-11-05 2014-05-08 Morphosys Ag Radiolabelled antibody and uses thereof
BR112016009919A2 (pt) * 2013-11-04 2017-12-05 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma

Also Published As

Publication number Publication date
CL2017001090A1 (es) 2018-01-05
SG11201703313SA (en) 2017-05-30
JP2018501297A (ja) 2018-01-18
CA2965745C (en) 2023-12-05
CN107207596A (zh) 2017-09-26
WO2016071355A1 (en) 2016-05-12
CA2965745A1 (en) 2016-05-12
JP7403505B2 (ja) 2023-12-22
KR20170078831A (ko) 2017-07-07
JP2021184722A (ja) 2021-12-09
BR112017009263A2 (pt) 2018-01-30
MY186929A (en) 2021-08-26
EA039658B1 (ru) 2022-02-22
HK1244014A1 (zh) 2018-07-27
NZ732019A (en) 2022-07-29
EA201790961A1 (ru) 2017-10-31
JP2019214582A (ja) 2019-12-19
PH12017500819A1 (en) 2017-10-02
AU2015341884A1 (en) 2017-06-08
MX2017005814A (es) 2017-08-02
AU2015341884B2 (en) 2020-09-17
CO2017005240A2 (es) 2017-10-31
IL251848A0 (en) 2017-06-29
EP3215541A1 (en) 2017-09-13
PE20171041A1 (es) 2017-07-19

Similar Documents

Publication Publication Date Title
MA40894A (fr) Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
HK1245171A1 (zh) 結合cd3和cd38的異二聚體抗體
HK1257164A1 (zh) 新型抗pd-l1抗體
IL255727A (en) Novel anti-pd-l1 antibodies
HK1246324A1 (zh) 抗pd-l1抗體
IL248007A0 (en) Bispecific antibodies that bind to cd38 and cd3
MA40889A (fr) Immunoglobulines héréro-dimériques reciblant des lymphocytes
SG10201603721TA (en) Anti-CTLA-4 Antibodies
SI3223845T1 (sl) Heterodimerna protitelesa, ki vežejo CD3 in CD20
HK1251055A1 (zh) 用於結構化多字段文件布局的自動化解釋
MA42829A (fr) Compositions dérivées de placenta et procédés pour les produire
MA41375A (fr) Anticorps igg bispécifiques et leurs procédés de préparation
MA39915A (fr) Composés de pladiénolide pyridine et leurs procédés d'utilisation
HK1256816A1 (zh) 新型抗人gpvi抗體及其用途
MA44517A (fr) Compositions d'immunoglobuline intraveineuse recombinante (rivig) et leurs procédés de production et d'utilisation
DK3250491T3 (en) Product turner and placer
MA45831A (fr) Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation
ZA201604024B (en) Improved feeding strategies and purification processes for monoclonal antibody production
GB201621446D0 (en) IL-11 antibodies
TH176441B (th) ระบบการผลิตและวิธีการผลิตสำหรับผลิตภัณฑ์ที่ประกอบด้วยไนโตรเจน และผลิตภัณฑ์ที่ถูกเลือกจากผลิตภัณฑ์หมัก/เพาะเลี้ยง
TH1501005423A (th) โมเลกุลยึดเกาะสำหรับ bcma และ cd3
ES1153808Y (es) Envase con productos de aperitivo
LU92551B1 (fr) Compositions et procédés améliorés pour complexes de borocarbohydrate
TH1601002436B (th) ผลิตภัณฑ์สวมใส่ชนิดกางเกงชั้นใน และวิธีการผลิตผลิตภัณฑ์นั้น
TH1501004666B (th) เครื่องจักรและวิธีการสำหรับการขึ้นรูปภาชนะบรรจุจากวัสดุเตรียมขึ้นรูปซึ่งนำพา โดยแบบหล่อที่ตามสืบเนื่องกันมา